There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Karyopharm Therapeutics (KPTI – Research Report) and Pliant Therapeutics (PLRX – Research Report) with bullish sentiments.
Karyopharm Therapeutics (KPTI)
Robert W. Baird analyst Colleen M. Kusy maintained a Buy rating on Karyopharm Therapeutics yesterday and set a price target of $10.00. The company’s shares closed last Thursday at $1.37, close to its 52-week low of $1.11.
According to TipRanks.com, Kusy is ranked 0 out of 5 stars with an average return of
Karyopharm Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $6.71.
See the top stocks recommended by analysts >>
Pliant Therapeutics (PLRX)
In a report issued on September 26, Joel Beatty from Robert W. Baird maintained a Buy rating on Pliant Therapeutics, with a price target of $44.00. The company’s shares closed last Thursday at $16.40, close to its 52-week low of $14.47.
According to TipRanks.com, Beatty is a 3-star analyst with an average return of
Pliant Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $48.82, which is a 193.4% upside from current levels. In a report issued on September 27, H.C. Wainwright also maintained a Buy rating on the stock with a $52.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on KPTI:
- Karyopharm price target lowered to $7 from $8 at Piper Sandler
- Karyopharm sees FY23 revenue $145M-$160M, consensus $150.34M
- Karyopharm reports Q2 EPS (29c), consensus (34c)
- Karyopharm Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
- KPTI Upcoming Earnings Report: What to Expect?
